Purity>95% (SDS-PAGE&SEC); Endotoxin Level<0.01EU/μg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| D412005-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $39.90 | |
| D412005-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $159.90 | |
| D412005-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $664.90 | |
| D412005-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,196.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<0.01EU/μg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Durvalumab (anti-PD-L1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to B7-H1 / PD-L1 / CD274, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Durvalumab (anti-PD-L1); MEDI4736; Durvalumab; MEDI 4736; Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (durvalumab); Recombinant Durvalumab Antibody; B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 27 |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | B7-H1 / PD-L1 / CD274 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Programmed cell death 1 ligand 1 inhibitor |
| Product Description | Durvalumab is an humanized anti-PD-L1 monoclonal antibody, completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| SDS-PAGE | 26.5 kDa (Light Chain) & 52.2 kDa (Heavy Chain), under reducing conditions; 180.0 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1428935-60-7 |
Durvalumab (anti-PD-L1) (D412005) - Flow Cytometry
Flow Cytometry analysis of PBMC cells labelling PD-L1 (red) with Durvalumab (anti-PD-L1) (D412005) . Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Durvalumab (anti-PD-L1) (D412005) - SEC
The purity of Durvalumab (anti-PD-L1) (D412005) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| IMGT/mAb-DB | 528 |
|---|---|
| Wikipedia | Durvalumab |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0404206 | Certificate of Analysis | Apr 08, 2024 | D412005 |
| ZJ24F0404207 | Certificate of Analysis | Apr 08, 2024 | D412005 |
| ZJ24F0404208 | Certificate of Analysis | Apr 08, 2024 | D412005 |
| 1. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.. Sci Rep, 7 (1): (5532). [PMID:28717238] |
